EVH
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a deep discount to assets and sales, but lacks earnings to support a valuation floor.
- P/S 0.19
- P/B 0.84
- Negative earnings make P/E irrelevant
- Forward P/E of 7.09 is speculative given revenue trends
Growth metrics are in a state of collapse, contradicting analyst optimism.
- Analyst target price of $5.18
- Revenue growth is sharply negative (-27.5%)
- Earnings surprises are heavily negative
Long-term trend is aggressively bearish with significant capital erosion.
- Historical periods of EPS beats in 2022-2023
- 5Y return of -85.2%
- 1Y return of -65.6%
Deterministic health scores indicate a company in financial distress.
- Current ratio > 1.0
- Piotroski F-Score 2/9
- Debt/Equity 2.38
- Negative ROE
Non-dividend paying growth/distressed stock.
- No dividend paid
- No dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EVH and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EVH
Evolent Health, Inc.
Primary
|
-85.2% | -91.1% | -65.6% | -59.9% | +37.9% | +10.2% |
|
TOI
The Oncology Institute, Inc.
Peer
|
-65.3% | +535.4% | +47.3% | -17.0% | +6.0% | +6.7% |
|
TBRG
TruBridge, Inc.
Peer
|
-22.7% | -18.7% | -3.7% | +17.2% | +51.5% | +9.2% |
|
LAB
Standard BioTools Inc.
Peer
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
|
SLN
Silence Therapeutics plc
Peer
|
-67.4% | +20.9% | +139.8% | +15.8% | +13.6% | +31.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EVH
Evolent Health, Inc.
|
BEARISH | $349.43M | - | -66.5% | -28.5% | $3.13 | |
|
TOI
The Oncology Institute, Inc.
|
BEARISH | $347.91M | - | -% | -12.1% | $3.52 | Compare |
|
TBRG
TruBridge, Inc.
|
NEUTRAL | $347.91M | 79.93 | 2.5% | 1.3% | $23.18 | Compare |
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | Compare |
|
SLN
Silence Therapeutics plc
|
BEARISH | $355.67M | - | -90.3% | -% | $7.53 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | BLACKLEY SETH | Chief Executive Officer | Stock Award | 58,921 | - |
| 2026-03-02 | WEINBERG JONATHAN D. | General Counsel | Stock Award | 4,910 | - |
| 2026-03-02 | SHAMS AAMMAAD | Officer | Stock Award | 1,686 | - |
| 2026-03-02 | MCCARTHY DANIEL JOSEPH | President | Stock Award | 39,281 | - |
| 2026-01-02 | SMITH JILL D | Director | Stock Award | 23,137 | - |
| 2026-01-02 | RAMOS MARIO | Chief Financial Officer | Stock Award | 587,500 | - |
| 2025-11-18 | SPRINGSTUBB BRENDAN B. | Director | Purchase | 10,000 | $38,199 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
The provided excerpts for EVH do not contain specific financial performance metrics or highlights. A primary risk identified is the company's reliance on third-party market data and forecasts that have not been independently verified, creating uncertainty regarding the achievement of projected outcomes.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning EVH from our newsroom.